This symposium took place on 16th June 2017, as a part of the European League Against Rheumatism (EULAR) 18th Annual Congress in Madrid, Spain
Chairpersons: Dennis McGonagle,1 Frank Behrens2
Speakers: Dennis McGonagle,1 Frank Behrens,2 Silvio Danese3
1. University of Leeds, Leeds, UK
2. Goethe University, Frankfurt, Germany
3. Humanitas University, Rozzano, Italy
Disclosure: Prof McGonagle has received grant/research support from Pfizer, MSD, Janssen, Celgene, and AbbVie. He has also received honoraria or consultation fees from Pfizer, MSD, Janssen, Celgene, UCB, Abbvie, and Novartis and has participated in speaker bureaus sponsored by Pfizer, MSD, Janssen, Celgene, AbbVie, and Novartis. Dr Behrens has received grant/research support from AbbVie, Janssen, Pfizer, Roche, Chugai, and Novartis. He has also received honoraria or consultation fees from AbbVie, Pfizer, Roche, Chugai, UCB, BMS, Celgene, MSD, Novartis, Biotest, Janssen, Genzyme, Lilly, and Sandoz. Prof Danese has received honoraria or consultation fees from AbbVie, AstraZeneca, Johnson & Johnson, MSD, Mundipharma, Takeda Millennium, Salix Pharmaceuticals, and Pfizer. He has also participated in speaker bureaus sponsored by AbbVie, AstraZeneca, Johnson & Johnson, MSD, Mundipharma, Takeda Millennium, Salix Pharmaceuticals, and Pfizer.
Acknowledgements: Writing assistance was provided by Reg Gomez, ApotheCom, London, UK.
Support: The publication of this article was funded by Janssen Pharmaceutica NV. The views and opinions expressed are those of the authors and not necessarily those of Janssen Pharmaceutica NV.
Citation: EMJ Rheumatol. 2017;5[Suppl 13]:10-16.
Prof McGonagle introduced the symposium and briefly described the aims of the meeting. Dr Behrens first discussed how findings from relevant psoriasis and psoriatic arthritis (PsA) registries can be applied to improve daily practice, and reflected on the real-life effectiveness of biologic therapies in the treatment of PsA. Prof McGonagle then followed with a discussion describing the key immunological pathways involved in psoriasis and PsA, evaluating the key similarities and differences in tissue and cytokine pathobiology in both conditions. Prof Danese then concluded the symposium by presenting on the pathophysiology of the interleukin (IL)-23 pathway in inflammatory bowel disease (IBD), reviewing the latest data for IL-23 inhibitors in treating IBD.
This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
The post Interleukin-23: The Common Link Between the Joint, the Gut, and the Skin? appeared first on European Medical Journal.